Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Sci Rep · 2025 · PMC12615611 · PMID 41233445

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Nevertheless, there is a strong trend that DAR + DOC + ADT provides the greatest survival benefits for patients with mHSPC, and typically outperforms doublet therapies across a number of populations 25 – 27 .

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.